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Mastitis in cows represents one of the most actual problems in 
intensive dairy production. The longtime different approaches to the 
treatment of mastitis have not offered a suitable solution, and the 
problem of mastitis is still present and acute. Prevention of pathogen 
penetration into the mammary gland, its colonization and multiplication 
impose a constant need for regular inspections of milk, as well as 
preventive and therapeutic measures to reduce the incidence of 
mastitis. Studies in the field of vaccination of ruminants against mastitis 
pathogens suggest a limited success in obtaining significant results in 
immunoprophylaxis. Considering the results of other researchers and 
our own research, and bearing in mind the problems mastitis caused 
by Staphylococcus aureus and Streptococcus agalactiae represent, 
the aim of this study was the preparation and testing of an indigenous 
vaccine prepared with two stable strains, SAU 7 (S. aureus) and SAG 3 
(Str.agalactiae). The dose was 5 mL/cow and consisted of inactivated 
bacterial S. aureus SAU 7 cells in a concentration of 1x1010 cfu/mL and 
Str. agalactiae SAG 3 in a concentration of 4 x 109 cfu/mL. The number 
of somatic cells in the milk samples during the whole study period was 
higher in vaccinated cows in both groups compared with the control, 
but this difference was not statistically significant. The concentration 
of immunoglobulin IgG in the milk of vaccinated cows was significantly 
higher than the concentration of this class of proteins in the milk of 
unvaccinated cows.
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INTRoDUCTIoN
Immunoprophylaxis against mastitis pathogens during the ‘70ties was 
based on polyvaccines, which consisted of immunogenic strains of staphylococci, 
streptococci and coliform bacteria, exotoxins and endotoxins. polyvalent vaccines 
have not proven to be successful, and their production was abandoned in favor 
of monovalent vaccines, which gave much better results. The vaccine against 
Staphylococcus aureus contains inactive S. aureus cells (giraudo, 1997; 
Hoedermaker, 1999), as well as Str. agalactiae cells (giraudo, 1997). a large 
number of studies indicate that in order to obtain an improved inactivated vaccine 
alpha and beta toxoids are added to S. aureus, as well as fragments of its capsule 
(Calzolari, 1997; Watson, 1996). Keskin et al. (2007) described the effects of a 
commercial vaccine which contained inactivated strains of S. aureus TC5, S. 
aureus TC8, E. coli, Str. agalactiae, Str. uberis, S. pyogenes, P. aeruginosa and 
A. pyogenes. A highly specific stable vaccine, produced in Tornau, was for the first 
time used for the immunization of a herd in germany (Hoedemaker, 1999). one 
vaccine dose measured 3.8x108 cfu/ml formalin inactivated S. aureus cells. No 
statistical significance in mastitis incidence between groups was established, nor 
was for the number of SCC in the milk samples. extensive testing was conducted 
by edinger (2000) who examined the vaccine prepared from two strains of S. 
aureus, previously inactivated with formalin. The vaccine measured a total 
bacterial cell count (TbC/ml) in a concentration of 1x1011 and 8.8x1010 of the other 
strain. The somatic cells count (SCC) in the milk was lower in the vaccinated 
group, but was statistically significant at the third sampling. A new approach in the 
preparation and application of vaccines was given by Carter (2003), the vaccine 
contained human cytomegalovirus on whose plasmid DNa out a direct expression 
of the Green fluorescent Staphyloccocal protein (GFP) was carried. The effects 
of the vaccine on the increase of antibodies against S. aureus which consisted of 
a polysaccharide capsule type 5 (T5), 8 (T8) and 336 (T336), were described by 
lee (2005) in his work. The experiment described by abubakar (2006) indicates 
that the group of rats vaccinated and revaccinated with an inactivated vaccine 
against Str. agalactiae exhibited a higher antibody titer compared to the group 
which received a single vaccine dose. The vaccine was prepared with a formalin 
inactivated strain of Str. agalactiae (1x109/ml) and applied to rats subcutaneously 
in a dose of 0.2 ml. In a study vakanjac et al. (2008) described the preparation of 
a vaccine applied in a dose of 5ml (S. aureus JR 3 in a quantity of 1x1010 cfu/ml, 
5 mg Sm capsule S. aureus 2286 strain). Cows were vaccinated two months and 
re-vaccinated one month before the expected partum. There was no statistical 
significance in the number of SCC values   of the control and vaccinated groups. 
However, a statistically significant difference was found in the values   of the levels 
of antibodies in immunized cows (0.697 oD) compared to the control group (0.438 
oD). ahmar (2008) described the preparation of a bivalent vaccine against mastitis 
caused by S. aureus and Str. agalactiae. The titre of specific anti streptococcal and 
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anti staphylococcal antibodies of the vaccinated group of rabbits was significantly 
increased compared with the control group. The vaccine prepared by leitner 
(2011) contained part of the membrane of the surface protein rTRap (recombinant 
Target RNAIII Activating Protein) and it is an integral component of protein 167 
aa, being a landmark of pathogenic staphylococcal strains. antibody levels in the 
first three months after vaccination were significantly higher in the experimental 
group of cows, as opposed to the number of SCC, which was higher in the control 
group. Chen (2012) prepared a staphylococcal enterotoxin a (rSea) recombinant 
vaccine and used as a carrier polylastic-co-glycolic acid (plga) microparticles. 
Test results showed a strong humoral response to increasing concentrations of 
antibodies against rSea and increased survival of mice infected with lethal doses 
of S. aureus.
maTeRIal aND meTHoDS
Vaccine preparation – The vaccine was prepared with two autochthonous 
strains which have displayed distinct biochemical features of S. aureus SaU 7 and 
Str. agalactiae Sag 3. both these strains were seeded on brain-Heart Infusion 
(Serva). The prepared 5 l brain-Heart Infusion was seeded with the isolated S. 
aureus SAU 7 strain. The so seeded media was incubated for 24h at 37˚C. After 
incubation to the nutrient agar were added 0.4% vol/vol formalin and once again 
incubated for 24h. after inactivation of the microorganism with formalin the culture 
was centrifuged at 7,000 rpm, 20 minutes, at 4˚C. The inactivation procedure was 
tested by seeding on blood agar and incubation at 37˚C for 24h. Lack of bacterial 
growth and hemolysis confirmed that the culture was successfully inactivated. 
after centrifugation the supernatant was discarded and the sediment resuspended 
in 0.9% NaCl, pH7.0. The resuspended sediment represented the first component 
of the vaccine.
The same procedure was repeated with the Str. agalactiae Sag 3 strain, and 
the resuspended sediment was used as the second component of the vaccine. In 
the resuspended sediments 0.4% vol/vol formalin, 0.001% wt/vol timerasol and 
3.5% wt/vol carrier aluminium hydroxide, were added.
The dose of the vaccine was 5ml/cow, containing inactivated bacterial 
S.aureus SaU 7 in a quantity of 1x1010 cfu/mL (first constituent) and Str. agalactiae 
Sag 3 in a quantity of 4 x 109 cfu/ml (second constituent). by preparing the vaccine 
in the described manner 151 vaccine doses (5 ml each) were obtained.
Vaccine sterility and toxicity tests
To test for sterility the vaccine was seeded into 2 test tubes containing serum 
broth, 2 test tubes containing nutritious broth, Jansen’s media with added starch 
and Jansen media with glucose added, nutritious oblique agar and blood agar. In 
none of the listed media aerobic or anaerobic bacterial growth was recorded. This 
proved that the vaccine was sterile.
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Toxicity was tested for on a total of 10 white mice, 2 guinea pigs, 4 sheep and 
5 pregnant cows (vakanjac et al., 2008).
Citology
The number of somatic cells was estimated by light miceoscopy, previously 
described by vakanjac et al. (2008).
Immunology tests
Due to a lack of commercial elISa tests special custom made tests for the 
purpose of the study were designed in order to determine the level of specific 
antibodies in the milk samples.
Preparation of direct ELISA test plates
The preparation of the antigen for elISa consisted of Staphylococcus 
aureus SaU 7, and Streptococcus agalactiae Sag 3 vaccine strains, inoculated 
into 10ml brain-heart broth (oxoid, UK), and incubated at 37°C for 24 hours. 
after incubation, 2 ml broth culture was centrifuged at 6000 rpm for 10 min. 
The supernatant was discarded and the cell sediment resuspended in 2 ml 
phosphate buffered saline- pbS, pH 7.4 (oxoid, UK). Thereon the suspensions 
were again centrifuged at 6000 rpm for 10 min and the supernatant discarded. 
The procedure was repeated twice. The obtained sediments were resuspended in 
5 mL ¼ Ringer solution (Oxoid, UK) with 2% Lysosime (Merck, Germany), 89 mM 
TRIS (merck, germany) and 2 mm eDTa (merck, germany) added. The solutions 
were incubated at 56°C for 30 min. after incubation the solution was well mixed 
on a vortex mixer, and 0.3% formaldehyde was added (Merck, Germany). The 
suspension was incubated at 4°C, for 24 hours. after incubation the suspension 
was heated in a thermoblock (Techne, germany) at 100°C for 30 min. Thereon 
the suspension was centrifuged at 6000 rpm for 10 min and the supernatant was 
collected. The supernatant contained the antigens diluted 1:10 with the coating 
buffer (mm Na2Co3/NaHCo3, pH 9,6, Sigma aldrich, germany). To each well was 
added 100 μL coating buffer solution. The coated ELISA plates were incubated 
at 4°C for 24 hours. after incubation the plates were rinsed three times with the 
rinsing solution (PBS, pH 7.4). To each of the wells 200 μL  of blocking buffer 
(3% casein hydrolysate/PBS, Oxoid, UK)  was added. The blocked plates were 
incubated at 4°C for 24 hours. after incubation the plates were rinsed three times 
with the rinsing solution (pbS, pH 7.4).
Experiment
Sixty pregnant dairy Holstein- freesian cows of similar age (4-5 years) were 
included in the study. experimental group 1 (e1) consisted of 20 cows, vaccinated 
two months prior to calving, and revaccinated a month before the expected 
term of delivery. experimental group 2 (e 2) consisted of 20 cows vaccinated 
one month before and revaccinateed two months after calving. The remaining 20 
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cows, considered as the control group (C), was vaccinated with a placebo vaccine 
(5 ml sterile saline).
milk samples were taken from all animals before vaccination (before the 
dry period) and after calving at monthly intervals before the first symptoms of 
clinical and sub-clinical mastitis. The milk samples were tested cytologically and 
bacteriologically in order to disclose the presence of S. aureus and Str. agalactiae.
ReSUlTS
In this chapter the given results are from a farm with a high yearly incidence of 
sub-clinical and clinical mastitis where the cows were vaccinated and revaccinated 
with stable strains S. aureus SaU 7 and Str. agalactiae Sag 3.
Microbiological testing 
The experiment lasted for 8 months, from the dry period, to the onset of 
clinical or subclinical mastitis caused by S. aureus and Str. agalactiae. milk samples 
taken from the control group (C) and experimental group 2 (e2) at the start of the 
trial tested positive for S. aureus in 6 samples (40%), and in experimental group 
1 (E1) in 8 samples (53.3%). At the end of the trial period S. aureus was isolated 
most often in the control group (53.3%). Experimental group 1 (E1) exhibited 4 
(26.6%) and group 2 (E2) 3 (20%) cows positive to S. aureus. Subclinical mastitis 
was diagnosed in 6 cows in the control group (40%), followed by 4 cows (26.6%) 
in the (E1), and in 3 cows (20%) in the (E2). Clinical S. aureus mastitis emerged 
only in the control group in 2 cases (13.3%). The cows from both experimental 
groups were not diagnosed with clinical mastitis (Table 1).
Table 1 occurrence of clinical and subclinical mastitis, caused by S. aureus at the beginning 
and end of the experiment.
Table 2. occurrence of clinical and subclinical mastitis caused by Str. agalactiae at the start 
and end of the trial
group n
S. aureus 
start
%
S. aureus 
end
%
Subclinical 
mastitis
%
Clinical 
mastitis
%
C 15 6 40 8 53.3 6 40.0 2 13.3
e1 15 8 53 4 26.6 4 26.0 / /
e2 15 6 40 3 20.0 3 20.0 / /
group N S. agalactiae 
start %
S. agalactiae 
end
%
Subclinical 
mastitis
%
Clinical 
mastitis
%
C 15 3 20 2 13,3 2 13,3 / /
e1 15 3 20 / / / / / /
e2 15 3 20 / / / / / /
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at the beginning of the experiment the milk samples from the control and 
(e1) and (e2), Str. agalactiae was isolated in 3 (20%) of cows in each group. At 
the end of the experiment Str. agalactiae was isolated only in two cows (13.3%) 
in the control group, while in the treated groups this microorganism was not 
isolated. Subclinical mastitis caused by Str. agalactiae was diagnosed in only two 
cows in the control group, while the causal agent was not isolated from cows 
from the vaccinated group. on the other hand, clinical mastitis caused by this 
microorganism was not diagnosed in any of the cows in the experiment (Table 2).
Milk somatic cell count (SCC)
The number of somatic cells (SCC) in 1 ml of milk was determined by cell 
counting under a light microscope by previously described means. The average 
value of SCC in 1 ml of milk obtained from cows in the control group (C) was 
405 215 ± 41 893, while the value for (e1) was 613 204 ± 38 123, and for (e2) 
527 681 ± 42 617. There was no statistical significance in the number of SCC 
during the entire period. In the control group of cows at the beginning of the 
dry period SCC was 972 409 ± 178 844 in 1 ml of milk, while (e1) and (e2) 
was 871 011 ± 122 639 and 946 320 ± 124 567, respectively. In the performed 
experiments, the average number of somatic cells in the milk samples in early 
lactation (colostrum) was for the control group 9450609 ± 170 027 in 1 ml of 
milk, in (e1) was 690 317 ± 1140126, and in (e2) SCC was 9390356 ± 114,175 
in 1 mL of milk. In the first month of the experiment the average number of SCC 
in 1 ml of milk was higher in the control group than in the treated groups (figure 
1). from the second month onward, the average number of SCC in 1 ml of milk 
in (e1) was greater than  in the control (C) and (e2). after seven months, the 
figure 1. The average values     of somatic cells (SCC) in 1 ml of milk 
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average number of SCC in 1 ml of milk was lower in the control group (401 351 
± 104 104), while in (e1 and e2) leveled at 623,507 ± 92,569 and 626,555 ± 
113,386 in 1 ml of milk.
Antibody milk titers 
Table 3 describes the percentages of clinical and subclinical S. aureus 
mastitis cases at the start and end of the experiment, as well as the anti 
staphylococcal antybodies titer in the milk samples of tested cows. The anti-
staphylococcal antibodies titer was lowest in the control group (0.65 ± 0.18 oD) 
and the incidence of cows affected with S. aureus increased from 40% to 53%. 
Subclinical mastitis was diagnosed in 6 cows (40%), and the clinical form was 
recorded in 2 animals (13%). In the (E1) titer of anti staphylococcal antibodies 
was 0.78 ± 0.21, and the percentage of mastitis caused by S. aureus with reduced 
from 53% to 26.6%. Subclinical mastitis was diagnosed in 4 (26.6%) cows, and 
the clinical form caused by S. aureus was not diagnosed. The highest titers of 
staphylococcal antibodies was measured in the (e2) and amounted to 0.81 ± 
0.21. The percentage of mastitis caused by S. aureus decreased from 40% to 
20%. Subclincal mastitis was diagnosed in 3 cows  (20%) and clinical mastitis 
caused by this microorganism was not reported.
Table 4 presents the percentages of subclinical and clinical mastitis caused 
by  Str. agalactiae at the beginning and end of the experiment, and the anti-
streptococcal antibody titers in the milk samples. from the table we see that in the 
control group anti-streptococcal antibody titer was the lowest (0.57 ± 0.39 oD), and 
the percentage of mastitis caused by Str. agalactiae in the milk was reduced from 
20% to 13.3%. Subclinical mastitis was diagnosed in 2 cows (13.3%) and clinical 
mastitis cases were not diagnosed. In (e1) streptococcal antibody titer was (1.00 
± 0.58oD) and subclincal and clinical Str.agalactiae mastitis was not reported. 
The highest of streptococcal antibody titer was measured in (e2) and amounted 
to 1.11 ± 0.64 oD, and subclinical and clinical mastitis cases were not reported in 
this group of animals.
group n
Incidence 
of S. aureus 
at the start 
(number of 
cows) 
Incidence 
of S. aureus 
at the end 
(number of 
cows)
Subclinical 
mastitis 
(number of 
cows) 
Clinical 
mastitis 
(number of 
cows)
anti 
staphylococal 
antibody titres
C 15 40%(6) 53.3%(8) 40.0%(6) 13.3%(2) 0.65 ± 0.18 oD
e1 15 53%(8) 26.6%(4) 26.6%(4) / 0.78 ± 0.21 oD
e2 15 40%(6) 20.0%(3) 20.0%(3) / 0.81 ± 0.21 oD
Table 3. Incidence of subclinical and clinical mastitis and anti staphylococcal antibodies in 
the milk samples
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DISCUSSIoN
The tests have shown that the number of somatic cells (SCC) in the milk 
samples at the beginning of the dry period was approximately within the published 
literature data. In the control group SCC was 972 409 ± 178 844 in 1 ml of milk, 
in (e1) SCC was about 871 011 ± 122 639, while for (e2) SCC was 946 319 ± 
124 567 in 1 ml of milk. In the performed experiments the average number of 
somatic cells  in early lactation was in the control group 945 609 ± 170 027, in 
(e1) was 690 316 ± 114 126, while for (e2) SCC was 936,356 ± 114,175 in 1 ml 
of milk. vakanjac et al. (2008) described an average SCC in the control group of 
551.223 ±248.429 cells/ml and for the treated group was 582.022±297.312  cells/
ml milk, this being very close to the values obtained in the here reported trial. 
The average value of SCC in 1 ml of milk in the control group was 405 215 ± 41 
893, in  experimental group 1 (e1) was 613 204  ± 38 123, while in  experimental 
group 2 (e2) was 5270681 ± 42 617, indicating that between groups there was 
no significant increase in SCC. The results coincide with the results published by 
Nordhaug (1994), giraudoa (1997), Hoedmaker (1999), edinger (2000), Keskin 
(2007) and prenafeta (2010), which did not report a significant increase in the 
number of SCC between groups.
During the entire experiment the values of the level of antibodies in 
experimental groups 1 and 2 were higher than for the control group. mean value    
of  specific  staphylococcal  antibodies  in  the  control  group  was  0.650  ±  0.18, 
(e1) 0.78 ± 0.21 oD, while the value   in the (e2) was 0.81 ± 0.21 oD. values   of 
specific staphylococcal antibody titer of the control group at the beginning of the 
experiment was 0.91 oD, but during the experiment the value decreased to 0.59 
oD. Staphylococcal antibody titer was 1.01 oD at the beginning of the experiment 
in the (e1), and during testing antibody levels decreased to 0.66 oD in contrast 
to the level of antibodies in (e2), which at the beginning of the test  was 0.99. The 
lowest reported value during the trial period amounted to 0.72 oD.
Significantly higher levels of antibodies in the experimental group than in 
the control group throughout the experiment were reported by Nordhaug (1994), 
group n
Incidence of 
Str. agalactiae 
at the start 
(number  
of cows)
Incidence of 
Str. agalactiae 
at the end 
(number  
of cows)
Subclinical 
mastitis 
(number  
of cows)
Clinical 
mastitis 
(number  
of cows)
anti 
staphylococal 
antibody titres
C 15 20 (3) 13,3 (2) 13,3 (2) / 0.57 ± 0.39 oD
e1 15 20 (3) / / / 1.00 ± 0.58 oD
e2 15 20 (3) / / / 1.11 ± 0.64 oD
Table 4. percentage of subclinical and clinical mastitis and anti-streptococcal antibody titer 
in the milk samples
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loeffer (1987), opdebeeck (1985), o’brien (2000), vakanjac (2008), pellegrino 
(2008) , perez (2009) and others. mean values   of the titer of staphylococcal specific 
antibodies in the milk samples of (E2) were significantly higher compared to (E1), 
similar to the results of Watson (1992), giraudo (1997) and prenafeta (2010), who 
recommended this method of immunization of dairy cows. In experimental group 
1 (vaccinated two months and revaccinated one month before expected calving) 
a higher level of anti staphylococcal antibodies was measured compared to the 
control group, but not when compared to (e2). The percentage of mastitis caused by 
S. aureus decreased from 53% to 26.6%, with only subclinical mastitis diagnosed. 
average level of anti-staphylococcal antibodies for group (e1) was 0.78 ± 0.21 oD, 
compared to the control group 0.65 ± 0.18 oD. The level of anti-staphylococcal 
antibodies in this group during the whole period of the experiment was lower than in 
group (E2). There was no statistical significance in the level of antibodies between 
groups (e1) and (e2) throughout the experiment, except in the fourth month from 
the start of the experiment. This is the period when a vaccine was administered 
to group (e2). based on these results, we believe that this level of antibodies was 
sufficient to prevent the emergence of new staphylococcal infection, and decrease 
the number of mastitis cases by the end of the experiment. Nickerson (1999) 
in his work revealed similar results of an increased level of anti-staphylococcal 
antibodies and decreased occurrence of staphylococcal infection of the mammary 
gland, after vaccination and revaccination prior to calving. In experimental groups 
1 and 2, anti-streptococcal antibody levels increased significantly compared to the 
control group. antibody level in the control group was 0.57 ± 0.39 oD, (e1) 1.00 ± 
0.58 and (e2) 1.11  ± 0.64 oD. Streptococcal mastitis was not reported in any of 
the experimental groups compared to the control where subclinical mastitis was 
diagnosed in 13.3% cows. The vaccine administered 45 days before and 60 days 
after parturition showed a significant increase in anti-staphylococcal and anti-
streptococcal antibodies in rabbits. ahmad (2008) suggested the possibility that 
the bivalent vaccine reduced the occurrence of clinical and subclinical mastitis 
caused by S. aureus and Str. agalactiae. Abubakar (2006) points to a significant 
increase of anti-streptococcal antibodies in rabbits after multiple vaccinations in 
relation to a single vaccine application, prepared from inactivated bacterial cells 
of Str. agalactiae.
CoNClUSIoNS
In cows vaccinated one month before and revaccinated two months after 
calving (experimental group 2), subclinical and clinical mastitis occurred in a 
significantly smaller percentage compared to the control cows. In both groups 
of vaccinated cows the number of somatic cells in the milk during the whole 
study period was higher than in the control group of cows, but this difference 
was not statistically significant. The concentration of immunoglobulin IgG in the 
milk of vaccinated cows was significantly higher than the concentration of this 
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class of proteins in the milk of unvaccinated cows. activation of humoral immune 
responses in cows vaccinated before and postpartum is far more pronounced 
than in cows that were vaccinated and revaccinated in the antepartal period.
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ocena efiKasnosti bivalentne vaKcine u ProfilaKsi  
nastanKa mastitisa Kod Krava
MAGAŠ V, VAKANJAC SLOBODANKA, PAVLOVIĆ V, VELEBIT B, MIRILOVIĆ M, 
MALETIĆ M, ĐURIĆ M i NEDIĆ SVETLANA
SADRŽAJ
Upala mlečne žlezde ili mastitis krava, predstavlja jedan od najaktuelnijih 
problema u intenzivnoj proizvodnji mleka. Dugogodišnji različiti pristupi lečenju 
mastitisa  nisu  dali  odgovarajuće  rešenje,  pa  je  problem  mastitisa  i  dalje 
prisutan i aktuelan. Sprečavanje prodora patogenog uzročnika u mlečnu žlezdu, 
njegovo naseljavanje i razmnožavanje, nameću stalnu potrebu za redovnom 
kontrolom mleka, kao i preduzimanje preventivnih i terapijskih mera u cilju 
smanjenja pojave nastanka mastitisa. preventivna mera je i terapija krava u 
zasušenju koja podrazumeva lokalnu aplikaciju antibiotika nakon poslednje 
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muže. Terapija krava u zasušenju treba u narednoj laktaciji da obezbedi što duži 
period neinficiranosti vimena, a obavezna je kod dijagnostikovanih subkliničkih 
mastitisa izazvanih sa Staphylococcus aureus i Streptococcus agalactiae.   
Radovi iz oblasti vakcinisanja preživara protiv uzročnika mastitisa ukazuju na 
ograničen uspeh u dobijanju značajnijih rezultata imunoprofilakse. S obzirom na 
rezultate drugih istraživača i sopstvenih preliminarnih istraživanja, a imajuću u 
vidu problem koji predstavljaju mastitisi uzrokovani Staphylococcus aureus-om i 
Streptococcus agalactiae, cilj istraživanja je bio priprema i ispitavanje autohtone 
vakcine pripremljene od dva štalska soja SaU 7 (S. aureus) i Sag 3 (Str. 
agalactiae).  Broj somatskih ćelija u uzorcima mleka tokom celog trajanja ogleda 
je bio viši u obe ispitivane vakcinisane grupe, u odnosu na kontrolnu, ali nema 
statističke značajnosti. Koncentracija imunoglobulina IgG u mleku vakcinisanih 
krava  je  bila  značajno  povećana  u  odnosu  na  koncentraciju  imunoglobulina 
nevakcinisane grupe. 
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